Why I'm Considering Leaning Heavily Into Pfizer

High-yield dividend stocks have long been a cornerstone of wealth-building strategies for savvy investors. Typically offering yields above 3%, these companies have consistently outperformed the S&P 500 over extended time frames when dividends are diligently reinvested. This outperformance stems from the powerful combination of accelerated compounding and the tendency for high-yield stocks to be temporarily undervalued.Pharmaceutical-powerhouse Pfizer (NYSE: PFE) has recently emerged as an intriguing candidate in the high-yield category. The drugmaker's stock price has taken a significant hit, tumbling over 30% in the past 36 months. This substantial decline has pushed its dividend yield to an attractive 5.73% at current levels, well above its historical average of approximately 3.3%.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool